A promising area of research for the laboratory diagnosis of AD is the analysis of cerebrospinal fluid (CSF), where the measurement of Aβ(40) and Aβ(42), total tau, and phospho-tau-181 (pTau181) can distinguish AD patients from healthy subjects with high specificity and sensitivity (10–12). This evidence concerns the gene MAPT and Alzheimer disease.